10x Genomics logo

10x GenomicsNASDAQ: TXG

Profile

Sector:

Healthcare

Country:

United States

IPO:

12 September 2019

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.65 B
-90%vs. 3y high
79%vs. sector
-vs. 3y high
-vs. sector
-89%vs. 3y high
61%vs. sector
-92%vs. 3y high
45%vs. sector

Price

after hours | Thu, 21 Nov 2024 00:48:11 GMT
$13.64-$0.16(-1.16%)

Dividend

No data over the past 3 years
$151.65 M$153.46 M
$151.65 M-$35.75 M

Analysts recommendations

Institutional Ownership

TXG Latest News

Torex Gold Receives Approval for Normal Course Issuer Bid
newsfilecorp.com19 November 2024 Sentiment: POSITIVE

Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces that it has received approval from the Toronto Stock Exchange (the "TSX") of its notice of intention to make a normal course issuer bid (the "NCIB"). Under the NCIB, Torex is authorized to purchase up to 7,116,777 of its common shares ("Common Shares"), representing approximately 10% of the public float as of November 13, 2024, during the period commencing on November 21, 2024 and ending on November 20, 2025.

Torex Gold Reports Results From The Ongoing 2024 EPO Exploration Program
newsfilecorp.com13 November 2024 Sentiment: POSITIVE

Results indicate strong potential to upgrade Inferred Resources to Indicated Resources and expand resources to the north of the deposit (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - November 13, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces assay results from the Company's ongoing drilling program at EPO. The results to date support Torex's goal of expanding resources to the north of the deposit and upgrading Inferred Resources to Indicated Resources.

Torex Gold Reports Q3 2024 Results
newsfilecorp.com06 November 2024 Sentiment: POSITIVE

Solid financial performance and robust cash generation driven by an all-in sustaining costs margin of 52% (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - November 6, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three and nine months ended September 30, 2024. Torex will host a conference call tomorrow morning at 9:00 AM (ET) to discuss the results.

Torex Gold Provides Q3 2024 Update on Media Luna Project and Increases 2024 Production Guidance
newsfilecorp.com30 October 2024 Sentiment: POSITIVE

Project 87% complete; plant tie-in schedule moves to February; first copper concentrate expected in Q1 (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides a Q3 2024 update on the development of its Media Luna Project ("Media Luna") and increases 2024 production guidance with a decision to undertake the tie-ins and upgrades to the processing plant in February 2025. Unless otherwise stated, progress and milestones referenced in this press release are as of September 30, 2024.

These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results
benzinga.com30 October 2024 Sentiment: POSITIVE

10x Genomics, Inc. TXG reported a loss for the third quarter on Tuesday.

10x Genomics, Inc. (TXG) Q3 2024 Earnings Call Transcript
seekingalpha.com29 October 2024 Sentiment: NEUTRAL

10x Genomics, Inc. (NASDAQ:TXG ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Cassie Corneau - Senior Director, Head of Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer and Co-Founder Adam Taich - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Doug Schenkel - Wolfe Research Dan Arias - Stifel Nicolaus Dan Brennan - TD Cowen Mason Carrico - Stephens Puneet Souda - Leerink Partners Rachel Vatnsdal - J.P. Morgan Kyle Mikson - Canaccord Genuity Patrick Donnelly - Citi Michael Ryskin - Bank of America Subbu Nambi - Guggenheim Securities Matt Larew - William Blair Matt Sykes - Goldman Sachs Operator Thank you for standing by.

10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com29 October 2024 Sentiment: POSITIVE

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
zacks.com29 October 2024 Sentiment: POSITIVE

10x Genomics (TXG) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.51 per share a year ago.

10x Genomics Reports Third Quarter 2024 Financial Results
prnewswire.com29 October 2024 Sentiment: POSITIVE

PLEASANTON, Calif. , Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024.

Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down
zacks.com28 October 2024 Sentiment: NEUTRAL

Per a preliminary report from 10x Genomics, the company's revenues will decline for the third quarter. Lower Instruments sales are likely to have been partially offset by consumable sales growth.

What type of business is 10x Genomics?

10x Genomics, Inc. is an American biotechnology company that develops and manufactures gene sequencing technology used in scientific research. Registered in 2012 in the state of Delaware. The company offers tools, consumables, and software for analyzing biological systems at a resolution and scale that allows for analysis at the cellular level. Integrated solutions are used by biotechnology companies specializing in fundamental research in the fields of biology and medicine, including oncology, immunology, and neurobiology.

What sector is 10x Genomics in?

10x Genomics is in the Healthcare sector

What industry is 10x Genomics in?

10x Genomics is in the Health Information Services industry

What country is 10x Genomics from?

10x Genomics is headquartered in United States

When did 10x Genomics go public?

10x Genomics initial public offering (IPO) was on 12 September 2019

What is 10x Genomics website?

https://www.10xgenomics.com

Is 10x Genomics in the S&P 500?

No, 10x Genomics is not included in the S&P 500 index

Is 10x Genomics in the NASDAQ 100?

No, 10x Genomics is not included in the NASDAQ 100 index

Is 10x Genomics in the Dow Jones?

No, 10x Genomics is not included in the Dow Jones index

When was 10x Genomics the previous earnings report?

No data

When does 10x Genomics earnings report?

The next expected earnings date for 10x Genomics is 14 February 2025